Literature DB >> 17962598

The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia.

António J Bastos-Leite1, Wiesje M van der Flier, Elisabeth C W van Straaten, Salka S Staekenborg, Philip Scheltens, Frederik Barkhof.   

Abstract

BACKGROUND AND
PURPOSE: Besides cerebrovascular disease, medial temporal lobe atrophy (MTA), a neuroimaging finding suggestive of degenerative pathology, has been shown in vascular dementia (VaD). However, it is unknown to what extent MTA contributes to the pattern of cognitive impairment observed in VaD. Therefore, our purpose was to investigate the relative contribution of cerebrovascular disease and MTA to cognitive impairment in patients fulfilling diagnostic criteria for VaD.
METHODS: We examined 590 patients (374 men; mean age, 73 years; standard deviation, 8) with probable VaD according to the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria at inclusion into a multicenter clinical trial. Cerebrovascular disease and the degree of MTA were evaluated by using MRI. Cognitive testing included the Mini-Mental State Examination, and the vascular dementia assessment scale.
RESULTS: On the basis of the operational definitions for the neuroimaging part of the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria, 485 (82.2%) patients had small vessel VaD and 153 (25.9%) had large vessel VaD. More than half (59.8%) of the patients had considerable MTA. Multiple linear regression analyses revealed that after correction for sex, age, education, and duration of dementia, neuropsychological tests showed that patients with higher grades of MTA or large vessel VaD had significantly worse general cognitive and executive functioning, whereas associations with small vessel disease were restricted to worse executive functioning.
CONCLUSIONS: Both MTA and large vessel disease contribute to global cognitive impairment in VaD. Small vessel disease contributes to executive dysfunction.

Entities:  

Mesh:

Year:  2007        PMID: 17962598     DOI: 10.1161/STROKEAHA.107.490102

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  28 in total

1.  An inverse association of cardiovascular risk and frontal lobe glucose metabolism.

Authors:  B Kuczynski; W Jagust; H C Chui; B Reed
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

2.  Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients.

Authors:  Mark W Logue; Holly Posner; Richard C Green; Margaret Moline; L Adrienne Cupples; Katherine L Lunetta; Heng Zou; Stephen W Hurt; Lindsay A Farrer; Charles Decarli
Journal:  Alzheimers Dement       Date:  2011-07-01       Impact factor: 21.566

3.  Neuropsychological indicators of preclinical Alzheimer's disease among depressed older adults.

Authors:  Nicole C Rushing; Natalie Sachs-Ericsson; David C Steffens
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2013-05-09

4.  "Cardiovascular dementia" reappraisal of an old concept and Giambattista Vico's course and recourse theory: is history repeating itself?

Authors:  Enrica Cecchi; Claudio Pedone
Journal:  Intern Emerg Med       Date:  2020-07-18       Impact factor: 3.397

5.  Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.

Authors:  Gustavo C Román; Stephen Salloway; Sandra E Black; Donald R Royall; Charles Decarli; Michael W Weiner; Margaret Moline; Dinesh Kumar; Rachel Schindler; Holly Posner
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

Review 6.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

Review 7.  Management of mixed dementia.

Authors:  Dina Zekry; Gabriel Gold
Journal:  Drugs Aging       Date:  2010-09-01       Impact factor: 3.923

8.  Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.

Authors:  Giancarlo Zito; Renato Polimanti; Valentina Panetta; Mariacarla Ventriglia; Carlo Salustri; Maria Cristina Siotto; Filomena Moffa; Claudia Altamura; Fabrizio Vernieri; Domenico Lupoi; Emanuele Cassetta; Paolo M Rossini; Rosanna Squitti
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

9.  Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage.

Authors:  Li Xiong; Gregoire Boulouis; Andreas Charidimou; Duangnapa Roongpiboonsopit; Michael J Jessel; Marco Pasi; Yael D Reijmer; Panagiotis Fotiadis; Alison Ayres; Emily Merrill; Kristin Schwab; Deborah Blacker; M Edip Gurol; Steven M Greenberg; Anand Viswanathan
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-20       Impact factor: 6.960

Review 10.  Using structural and diffusion magnetic resonance imaging to differentiate the dementias.

Authors:  Sana Suri; Anya Topiwala; Clare E Mackay; Klaus P Ebmeier; Nicola Filippini
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.